Fertility and Sterility
Volume 94, Issue 1 , Pages 371-374 , June 2010

Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes

  • Mehmet Murat Naki, M.D.

      Affiliations

    • Obstetrics and Gynecology Department, Dr. Lutfi Kirdar Kartal Research and Training Hospital, Kartal, Istanbul, Turkey
    • Corresponding Author InformationReprint requests: Dr. Mehmet Murat Naki, Cihat Saran Sok. Cagdas Ap. A Blok, No: 11/3, 34841 Kucukyali, Maltepe-Istanbul, Turkey (FAX: 90-216-441-51-62).
    • ,
  • Cevahir Tekcan, M.D.

      Affiliations

    • Obstetrics and Gynecology Department, Medipol Hospital, Kadikoy, Istanbul, Turkey
    • ,
  • Nahit Ozcan, M.D.

      Affiliations

    • Radiology Department, Sonomed Imaging Center, Kadikoy, Istanbul, Turkey
    • ,
  • Meliha Cebi, M.D.

      Affiliations

    • Radiology Department, Sonomed Imaging Center, Kadikoy, Istanbul, Turkey

Received 6 July 2009 ,Revised 23 September 2009 ,Accepted 23 September 2009.

References 

  1. Cheng MH, Chao HT, Wang PH. Medical treatment for uterine myomas. Taiwan J Obstet Gynecol. 2008;47:18–23
  2. Rabinovici J, Stewart E. New interventional techniques for adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20:617–636
  3. Mercorio F, De Simone R, Di Spiezio Sardo A, Cerrota G, Bifulco G, Vanacore F, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67:277–280
  4. Wood C. Menorrhagia: a management update. Mod Med Aust. 1999;42:65–75
  5. Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol. 2001;108:74–86
  6. Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007;75(6 Suppl):99–103
  7. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;(4):CD002126
  8. Wildemeersch D, Schacht E. The effects on menstrual blood loss in women with uterine fibroids of a novel “frameless” intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2002;102:74–79
  9. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79:189–193
  10. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003;79:1194–1198
  11. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol. 1995;85:977–982
  12. de Jonge ET, Yigit R, Molenberghs G, Straetmans D, Ombelet W. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system. Contraception. 2007;76:91–95
  13. Busfield RA, Farquhar CM, Sowter MC, Lethaby A, Sprecher M, Yu Y, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. Br J Obstet Gynaecol. 2006;113:257–263
  14. Andrade ATL, Souza JP, Shaw ST, Belsey EM, Rowe PJ. Menstrual blood loss and body iron stores in Brazilian women. Contraception. 1991;43:241–249
  15. Monteiro I, Bahamondes L, Diaz J, Perrotti M, Petta C. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception. 2002;65:325–328
  16. Diaz J, Bahamondes L, Monteiro I, Petta C, Hidalgo MM, Arce XE. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinans, Brazil. Contraception. 2000;62:59–61
  17. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. Br J Obstet Gynaecol. 2000;107:335–339
  18. Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;7:193–198
  19. Rizkalla HF, Higgins M, Kelehan P, O'Herlihy C. Pathological findings associated with the presence of a Mirena intrauterine system at hysterectomy. Int J Gynecol Pathol. 2008;27:74–78
  20. Jondet M, Letellier B, Verdys M. Endometrial vascularization in levonorgestrel intrauterine device users; computerized microvessel measurement study. Contraception. 2005;71:60–64
  21. Tasci Y, Caglar GS, Kayikcioglu F, Cengiz H, Yagci B, Gunes M. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus. Arch Gynecol Obstet. 2009;280:39–42
  22. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception. 2007;75(6 Suppl):S161–S166(review)

 M.M.N. has nothing to disclose. C.T. has nothing to disclose. N.O. has nothing to disclose. M.C. has nothing to disclose.

PII: S0015-0282(09)03798-4

doi: 10.1016/j.fertnstert.2009.09.048

Fertility and Sterility
Volume 94, Issue 1 , Pages 371-374 , June 2010

Article Tools